Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations
Proto-Oncogene Proteins B-raf
0301 basic medicine
Neurofibromin 1
Neurofibromatoses
DNA Mutational Analysis
Antineoplastic Agents
Genomics
Middle Aged
Nerve Sheath Neoplasms
3. Good health
Gene Expression Regulation, Neoplastic
03 medical and health sciences
Genes, ras
Chemotherapy, Adjuvant
Mutation
Biomarkers, Tumor
Humans
Female
Radiotherapy, Adjuvant
Molecular Targeted Therapy
Protein Kinase Inhibitors
Cyclin-Dependent Kinase Inhibitor p16
Cyclin-Dependent Kinase Inhibitor p15
DOI:
10.6004/jnccn.2018.7033
Publication Date:
2018-08-11T17:15:16Z
AUTHORS (5)
ABSTRACT
Background: The aim of this study was to determine the frequency alterations in BRAF and other RAS/RAF genes, as well targetable pathways malignant peripheral nerve sheath tumors (MPNSTs). Patients Methods: Pathology specimens were available for 2 cohorts: (1) patients with MPNST at Swedish Cancer Institute (n=17) from 2004 through 2016, (2) evaluated >300 genomic Foundation Medicine 2014 2016 (n=186; including BRAF-mutated MPNST). Results: Of 201 MPNSTs, 13 (6.5%) demonstrated alterations. In cohort, 10 84 (11.9%) no NF1 had mutations (5 V600E, 5 other), did 3 102 (2.9%) (1 other). 47% an alteration least one gene pathway (not or BRAF); 46% PI3 pathway, 70% having 1 pathways; 57% a CDKN2A (80% 71% NF1-altered patients); DNA repair genes. MPNST, both wild-type NF1-mutated, often harbor changes related CDKN2A/B. V600E occur BRAF, suggesting need second-generation activating inhibitors. concurrence and/or CDKN2A/B mutations, particular, may be significant transformation neurologic benign malignant. Conclusions: All MPNSTs would benefit comprehensive analysis. Treatments targeted RAS/RAF, repair, should used developed treat uncommon tumor.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (30)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....